2018 Diarrhea Drug Development - Pipeline Analysis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “2018 Diarrhea Drug Development- Pipeline Analysis Report” report has been added to ResearchAndMarkets.com’s offering.
With an estimated 1.5 million to 2 million people being affected worldwide, Diarrhea is the most catastrophic disease causing morbidity among children. Developing and poor countries are most susceptible to diarrhea.
To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Diarrhea pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Diarrhea pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Diarrhea pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Key Topics Covered
1 Diarrhea Pipeline Analysis
2 Diarrhea - Company Wise Pipeline Analysis
3 Diarrhea R&D Pipeline Snapshots
4 Recent Developments in Diarrhea Pipeline
Companies FeaturedAche Laboratories Actelion Pharmaceuticals Ltd Allergan Plc Anatara Lifesciences Limited Ardelyx Inc Axim Biotechnologies AzurRx BioPharma Inc Bharat Biotech International Ltd ConSynance Therapeutics Cosmo Pharmaceuticals NV Dong-A ST Co GlaxoSmithKline Glycosyn LLC ImmuneBiotech AB LTT Bio-Pharma Co Miyarisan Pharmaceutical Napo Pharmaceuticals In Nippon Shinyaku Co Ltd Nobilis Therapeutics Novartis AG Orphomed Inc OstriGen Pfizer Inc Rebiotix Inc Recce Ltd RedHill Biopharma Ltd RxBio Inc SK Biopharmaceuticals Sumitomo Dainippon Pharma Summit Therapeutics Plc Symberix Inc Synergy Pharmaceuticals Synthetic Biologics Inc Tasly Pharmaceutical Group Co Ltd And many more...
For more information about this report visit https://www.researchandmarkets.com/research/gf9l7v/2018_diarrhea?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005452/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Drug Discovery,Gastrointestinal Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/12/2018 08:54 AM/DISC: 07/12/2018 08:54 AM